Industry analysis and company moves underscore a pivot: contract development and manufacturing organizations (CDMOs) are now strategic partners for cell and gene therapy scale-up. Reports stress the need for platform-based manufacturing, analytical depth and faster tech transfers to meet rising demand and regulatory expectations. Ritedose, now owned by Novo Holdings, is expanding its cGMP labs and microbiology capacity to support a projected output of 2.6 billion doses annually, illustrating how CDMOs are investing to capture generics and specialty drug manufacturing work. Large CDMOs positioning for integrated CMC, logistics and regulatory support are becoming essential to de-risking advanced therapy programs.